Tech Company Financing Transactions
TRIANA Biomedicines Funding Round
TRIANA Biomedicines closed a $110 million funding round on 4/6/2022. Investors included Lightspeed Venture Partners, Logos Capital and Pfizer Venture Investments.
Transaction Overview
Company Name
Announced On
4/6/2022
Transaction Type
Venture Equity
Amount
$110,000,000
Round
Undisclosed
Investors
Proceeds Purpose
funding to establish a best-in-class, scalable platform to discover and develop "molecular glues"
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 Totten Pond Road, Suite 120
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
TRIANA Biomedicines is a venture-backed biopharmaceutical company leading a transformative approach to discover and develop novel small molecules to treat disease. Our technology enables us to identify molecules that promote the interaction between a target and another protein in a way that alters the fate or function of the target protein. These innovative "molecular glues" allow us to treat disease in entirely new ways by pursuing highly disease relevant targets that have long been considered undruggable or are inadequately addressed.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Patrick Trojer
Chief Scientific Officer
Jean-Christophe Harmange
Chief Technical Officer
Jesse Chen
Browse more venture capital transactions:
Prev: 4/6/2022: Grafana Labs venture capital transaction
Next: 4/6/2022: SeeMetrics venture capital transaction
Share this article
Where The Data Comes From
We document all VC transactions involving tech companies. VC investment data records reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs